Alumis Inc Stock Price, News & Analysis

Alumis Inc. (ALMS) has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program evaluating ESK-001, a next-generation oral TYK2 inhibitor, for treating moderate-to-severe plaque psoriasis. The program includes two parallel Phase 3 trials with over 1,700 patients enrolled, with topline results expected in early Q1 2026. ESK-001 aims to address current treatment challenges by offering a well-tolerated oral alternative to injectable biologics, potentially delivering durable, biologic-like clinical responses. The ONWARD program consists of ONWARD1 and ONWARD2 (24-week trials), plus ONWARD3, an optional long-term extension trial to assess durability and safety.

Alumis Inc. (NASDAQ: ALMS) has completed its merger with ACELYRIN, Inc., creating a leading clinical-stage biopharma company focused on immune-mediated diseases. Under the merger terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share. ACELYRIN's stock has been delisted from NASDAQ.

The merger significantly strengthens Alumis' balance sheet, extending its cash runway into 2027. The combined company aims to advance its late-stage portfolio through multiple planned key data readouts. Morgan Stanley advised Alumis, while Guggenheim Securities advised ACELYRIN in the transaction.

Alumis (NASDAQ: ALMS) reported its Q1 2025 financial results and key developments. The company ended Q1 with $208.7 million in cash and equivalents. Revenue included $17.4 million from Kaken Pharmaceutical licensing agreement. Net loss widened to $99.0 million compared to $49.8 million in Q1 2024. R&D expenses increased to $96.6 million from $42.0 million YoY. The company is progressing toward a merger with ACELYRIN, expected to close in Q2 2025, with Alumis stockholders owning 52% of the combined entity. The merged company will have a pro forma cash position of $737 million, providing runway into 2027. Key pipeline developments include anticipated Phase 3 topline data for ESK-001 in psoriasis (Q1 2026) and Phase 2b data in systemic lupus erythematosus (2026).

Alumis Inc. (ALMS) stockholders have approved all proposals necessary for the pending merger with ACELYRIN, INC. (SLRN). The merger, announced at a Special Meeting of Stockholders, is expected to close in Q2 2025, subject to customary closing conditions. CEO Martin Babler expressed gratitude for stockholder support and highlighted that the merger would strengthen the company's financial foundation to advance breakthroughs in immune-mediated diseases. Alumis will file the final voting results in a Form 8-K with the SEC.

Alumis (NASDAQ: ALMS) and ACELYRIN have announced an amended merger agreement with revised ownership terms. Under the new agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share, resulting in Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning 48% of the combined company.

The merger aims to create a leading clinical-stage immunology company with enhanced financial flexibility. The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024, with funding expected to last into 2027. The transaction has received unanimous approval from both companies' boards, with stockholder voting agreements already secured from 62% of Alumis and 24% of ACELYRIN shareholders.

Special stockholder meetings are scheduled for May 13, 2025, with the transaction expected to close in Q2 2025, subject to stockholder approval and customary closing conditions.

Alumis (NASDAQ: ALMS) and ACELYRIN have filed a definitive proxy statement for their proposed merger, scheduled for completion in Q2 2025. The merger will create a late-stage clinical biopharma company focused on immune-mediated diseases with a pro forma cash position of $737 million, providing runway into 2027.

Key pipeline milestones include Phase 3 ONWARD trials for ESK-001 in psoriasis (1Q 2026), Phase 2b LUMUS trial in lupus (2026), Phase 2 trial initiation for A-005 in MS, and development of lonigutamab for thyroid eye disease.

Under the agreement, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock per share, resulting in Alumis stockholders owning 55% and ACELYRIN stockholders owning 45% of the combined company. Special stockholder meetings will be held virtually on May 13, 2025, with a record date of April 1, 2025.

Alumis (NASDAQ: ALMS) and Kaken Pharmaceutical have announced a collaboration and licensing agreement for ESK-001, a next-generation oral TYK2 inhibitor, in Japan. The deal includes $40 million in upfront and near-term co-development payments during 2025-2026, with potential for additional $140 million in milestone and field option payments, plus tiered royalties ranging from low double-digits to twenties on net sales.

Kaken will handle clinical development, regulatory approvals, and commercialization of ESK-001 in Japan for dermatology indications, with an option to expand into rheumatological and gastrointestinal diseases. The company will also contribute to global development costs, while Alumis retains rights in all other regions. The partnership builds on ESK-001's positive Phase 2 clinical data.

Alumis (NASDAQ: ALMS) reported its 2024 financial results and key milestones. The company presented promising 52-week Phase 2 STRIDE OLE data for ESK-001, their next-generation oral TYK2 inhibitor for psoriasis, with Phase 3 ONWARD program results expected in Q1 2026. They also shared positive Phase 1 data for A-005, their CNS-penetrant TYK2 inhibitor, with Phase 2 MS trials starting in H2 2025.

A significant merger with ACELYRIN was announced, expected to close in Q2 2025, creating a combined entity with Alumis stockholders owning 55%. The merged company will have approximately $737 million in cash (as of December 31, 2024), extending runway into 2027.

Financial highlights for 2024 include:

• Cash position: $288.3 million
• R&D expenses: $265.6 million (up from $137.7 million in 2023)
• G&A expenses: $35.2 million (up from $20.5 million in 2023)
• Net loss: $294.2 million (compared to $155.0 million in 2023)

Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company focused on developing oral precision therapies for immune-mediated diseases, has announced its participation in Leerink's 2025 Global Healthcare Conference.

Company President and CEO Martin Babler will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 10:40 am ET. Interested parties can access a live webcast of the presentation through the 'Events' page in the 'Investors' section of the Alumis website.